NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., trading under the ticker NRXP, is a biopharmaceutical company that reached the public markets through a SPAC merger with Big Rock Partners Acquisition Corp., sponsored by Big Rock Partners. The blank-check vehicle completed its IPO in 2018, targeting the healthcare and life sciences sector before announcing its business combination with clinical-stage drugmaker NeuroRx, Inc. The 10-Q quarterly report filed November 14, 2019, under accession number 0001654954-19-012962, reflects the SPAC's ongoing reporting obligations during its pre-combination search period. The de-SPAC transaction subsequently closed in 2021, with the combined entity operating as NRx Pharmaceuticals. Sign up on SpacDesk for the full filing history, deal timeline, and data on hundreds of SPAC transactions across every sector.